Clinical Trial Update: A Phase 1b Study to Assess the Safety and Anti-inflammatory Effects of Two Different Doses of SRT2104 in Patients With Ulcerative Colitis [Phase 1]

View source ↗

Summary

A Phase 1b study evaluated the safety and anti-inflammatory effects of two doses of SRT2104 in patients with Ulcerative Colitis, and the trial has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ulcerative Colitis

Drugs mentioned

• SRT2104 (SRT2104)

Snippet

Sponsor: Sirtris, a GSK Company | Conditions: Colitis, Ulcerative | Phase 1 | Status: COMPLETED